CRISPR Technology in Disease Management: An Updated Review of Clinical Translation and Therapeutic Potential

Abstract

CRISPR-Cas9 technology has rapidly advanced as a transformative genome-editing platform, facilitating precise genetic modifications and expanding therapeutic opportunities across various diseases. This review explores recent developments and clinical translations of CRISPR applications in oncology, genetic and neurological disorders, infectious diseases, immunotherapy, diagnostics, and epigenome editing. CRISPR has notably progressed in oncology, where it enables the identification of novel cancer drivers, elucidation of resistance mechanisms, and improvement of immunotherapies through engineered T cells, including PD-1 knockout CAR-T cells. Clinical trials employing CRISPR-edited cells are demonstrating promising results in hematologic malignancies and solid tumours. In genetic disorders, such as hemoglobinopathies and muscular dystrophies, CRISPR-Cas9 alongside advanced editors like base and prime editors show significant potential for correcting pathogenic mutations. This potential was affirmed with the FDA's first approval of a CRISPR-based therapy, Casgevy, for sickle cell disease in 2023. Neurological disorders, including Alzheimer's, ALS, and Huntington's disease, are increasingly targeted by CRISPR approaches for disease modelling and potential therapeutic intervention. In infectious diseases, CRISPR-based diagnostics such as SHERLOCK and DETECTR provide rapid, sensitive nucleic acid detection, particularly valuable in pathogen outbreaks like SARS-CoV-2. Therapeutically, CRISPR systems target viral and bacterial genomes, offering novel treatment modalities. Additionally, CRISPR-mediated epigenome editing enables precise regulation of gene expression, expanding therapeutic possibilities. Despite these advances, significant challenges remain, including off-target effects, delivery methodologies, immune responses, and long-term genomic safety concerns. Future improvements in editor precision, innovative delivery platforms, and enhanced safety assessments will be essential to fully integrate CRISPR-based interventions into standard clinical practice, significantly advancing personalised medicine.

Keywords

cancers / CRISPR-Cas systems / epigenome editing / genetic therapy / iPSC / molecular diagnostic techniques / nervous system diseases / personalised medicine

References

[1] K. Deshpande, A. Vyas, A. Balakrishnan, and D. Vyas, “Clustered Regularly Interspaced Short Palindromic Repeats/Cas9 Genetic Engineering: Robotic Genetic Surgery,” American Journal of Robotic Surgery 2, no. 1 (2015): 49–52.

[2] J. A. Doudna and E. Charpentier, “Genome Editing. The New Frontier of Genome Engineering With CRISPR-Cas9,” Science 346, no. 6213 (2014): 1258096.

[3] D. Rath, L. Amlinger, A. Rath, and M. Lundgren, “The CRISPR-Cas Immune System: Biology, Mechanisms and Applications,” Biochimie 117 (2015): 119–128.

[4] R. Barrangou and L. A. Marraffini, “CRISPR-Cas Systems: Prokaryotes Upgrade to Adaptive Immunity,” Molecular Cell 54, no. 2 (2014): 234–244.

[5] M. Asmamaw and B. Zawdie, “Mechanism and Applications of CRISPR/Cas-9-Mediated Genome Editing,” Biologics 15 (2021): 353–361.

[6] H. Chen, Y. Fu, K. Feng, et al., “Polydopamine-Coated UiO-66 Nanoparticles Loaded With Perfluorotributylamine/Tirapazamine for Hypoxia-Activated Osteosarcoma Therapy,” Journal of Nanobiotechnology 19, no. 1 (2021): 298.

[7] D. Gleditzsch, P. Pausch, H. Müller-Esparza, et al., “PAM Identification by CRISPR-Cas Effector Complexes: Diversified Mechanisms and Structures,” RNA Biology 16, no. 4 (2019): 504–517.

[8] F. Jiang and J. A. Doudna, “CRISPR-Cas9 Structures and Mechanisms,” Annual Review of Biophysics 46, no. 1 (2017): 505–529.

[9] J. Doudna, “CRISPR Book Review—Doudna Responds,” Nature 547, no. 7662 (2017): 162.

[10] Y. Yang, J. Xu, S. Ge, and L. Lai, “CRISPR/Cas: Advances, Limitations, and Applications for Precision Cancer Research,” Frontiers in Medicine 8 (2021): 649896.

[11] M. Liu, W. Zhang, C. Xin, et al., “Global Detection of DNA Repair Outcomes Induced by CRISPR-Cas9,” Nucleic Acids Research 49, no. 15 (2021): 8732–8742.

[12] F. Hille and E. Charpentier, “CRISPR-Cas: Biology, Mechanisms and Relevance,” Philosophical Transactions of the Royal Society, B: Biological Sciences 371, no. 1707 (2016): 20150496.

[13] T. S. Nambiar, L. Baudrier, P. Billon, and A. Ciccia, “CRISPR-Based Genome Editing Through the Lens of DNA Repair,” Molecular Cell 82, no. 2 (2022): 348–388.

[14] M. R. Lieber, “The Mechanism of Double-Strand DNA Break Repair by the Nonhomologous DNA End-Joining Pathway,” Annual Review of Biochemistry 79 (2010): 181–211.

[15] C. H. Lau, C. Tin, and Y. Suh, “CRISPR-Based Strategies for Targeted Transgene Knock-In and Gene Correction,” Faculty Reviews 9 (2020): 20.

[16] S.-W. Wang, C. Gao, Y. M. Zheng, et al., “Current Applications and Future Perspective of CRISPR/Cas9 Gene Editing in Cancer,” Molecular Cancer 21, no. 1 (2022): 57.

[17] M. F. Rasul, B. M. Hussen, A. Salihi, et al., “Strategies to Overcome the Main Challenges of the Use of CRISPR/Cas9 as a Replacement for Cancer Therapy,” Molecular Cancer 21, no. 1 (2022): 64.

[18] J. A. Doudna and E. Charpentier, “The New Frontier of Genome Engineering With CRISPR-Cas9,” Science 346, no. 6213 (2014): 1258096.

[19] X. Wu, A. J. Kriz, and P. A. Sharp, “Target Specificity of the CRISPR-Cas9 System,” Quantitative Biology 2, no. 2 (2014): 59–70.

[20] Z. Liu, H. Dong, Y. Cui, L. Cong, and D. Zhang, “Application of Different Types of CRISPR/Cas-Based Systems in Bacteria,” Microbial Cell Factories 19, no. 1 (2020): 172.

[21] H. X. Zhang, Y. Zhang, and H. Yin, “Genome Editing With mRNA Encoding ZFN, TALEN, and Cas9,” Molecular Therapy 27, no. 4 (2019): 735–746.

[22] M. S. Schubert, B. Thommandru, J. Woodley, et al., “Optimized Design Parameters for CRISPR Cas9 and Cas12a Homology-Directed Repair,” Scientific Reports 11, no. 1 (2021): 19482.

[23] N. G. Castro, J. Bjelic, G. Malhotra, et al., “Comparison of the Feasibility, Efficiency, and Safety of Genome Editing Technologies,” International Journal of Molecular Sciences 22, no. 19 (2021): 10355.

[24] H. Li, Y. Yang, W. Hong, M. Huang, M. Wu, and X. Zhao, “Applications of Genome Editing Technology in the Targeted Therapy of Human Diseases: Mechanisms, Advances and Prospects,” Signal Transduction and Targeted Therapy 5, no. 1 (2020): 1.

[25] C. Xue and E. C. Greene, “DNA Repair Pathway Choices in CRISPR-Cas9-Mediated Genome Editing,” Trends in Genetics 37, no. 7 (2021): 639–656.

[26] Y. Hisano, T. Sakuma, S. Nakade, et al., “Precise In-Frame Integration of Exogenous DNA Mediated by CRISPR/Cas9 System in Zebrafish,” Scientific Reports 5 (2015): 8841.

[27] J. P. Zhang, X. L. Li, G. H. Li, et al., “Efficient Precise Knockin With a Double Cut HDR Donor After CRISPR/Cas9-Mediated Double-Stranded DNA Cleavage,” Genome Biology 18, no. 1 (2017): 35.

[28] K. Yoshimi, Y. Kunihiro, T. Kaneko, H. Nagahora, B. Voigt, and T. Mashimo, “ssODN-Mediated Knock-In With CRISPR-Cas for Large Genomic Regions in Zygotes,” Nature Communications 7 (2016): 10431.

[29] M. Kosicki, K. Tomberg, and A. Bradley, “Repair of Double-Strand Breaks Induced by CRISPR-Cas9 Leads to Large Deletions and Complex Rearrangements,” Nature Biotechnology 36, no. 8 (2018): 765–771.

[30] J. Huang, Y. Zhou, J. Li, A. Lu, and C. Liang, “CRISPR/Cas Systems: Delivery and Application in Gene Therapy,” Frontiers in Bioengineering and Biotechnology 10 (2022): 942325.

[31] M. Zhang, E. A. Eshraghian, O. A. Jammal, Z. Zhang, and X. Zhu, “CRISPR Technology: The Engine That Drives Cancer Therapy,” Biomedicine & Pharmacotherapy 133 (2021): 111007.

[32] C. K. S. Karlson, S. N. Mohd-Noor, N. Nolte, and B. C. Tan, “CRISPR/dCas9-Based Systems: Mechanisms and Applications in Plant Sciences,” Plants (Basel) 10, no. 10 (2021): 102055.

[33] L. Huang, C. Yang, Y. Chen, H. Deng, Z. Liao, and H. Xiao, “CRISPR-Mediated Base Editing: Promises and Challenges for a Viable Oncotherapy Strategy,” Human Gene Therapy 34, no. 15–16 (2023): 669–681.

[34] E. M. Porto, A. C. Komor, I. M. Slaymaker, and G. W. Yeo, “Base Editing: Advances and Therapeutic Opportunities,” Nature Reviews. Drug Discovery 19, no. 12 (2020): 839–859.

[35] R. J. Marina, K. W. Brannan, K. D. Dong, B. A. Yee, and G. W. Yeo, “Evaluation of Engineered CRISPR-Cas-Mediated Systems for Site-Specific RNA Editing,” Cell Reports 33, no. 5 (2020): 108350.

[36] M. Rezazade Bazaz, M. M. Ghahramani Seno, and H. Dehghani, “Transposase-CRISPR Mediated Targeted Integration (TransCRISTI) in the Human Genome,” Scientific Reports 12, no. 1 (2022): 3390.

[37] H. A. Rees and D. R. Liu, “Base Editing: Precision Chemistry on the Genome and Transcriptome of Living Cells,” Nature Reviews Genetics 19, no. 12 (2018): 770–788.

[38] D. B. T. Cox, J. S. Gootenberg, O. O. Abudayy, et al., “RNA Editing With CRISPR-Cas13,” Science 358, no. 6366 (2017): 1019–1027.

[39] A. Apostolopoulos, N. Kawamoto, S. Y. A. Chow, et al., “dCas13-Mediated Translational Repression for Accurate Gene Silencing in Mammalian Cells,” Nature Communications 15, no. 1 (2024): 2205, https://doi.org/10.1038/s41467-024-46412-7.

[40] O. O. Abudayyeh, J. S. Gootenberg, S. Konermann, et al., “C2c2 Is a Single-Component Programmable RNA-Guided RNA-Targeting CRISPR Effector,” Science 353, no. 6299 (2016): aaf5573.

[41] A. V. Anzalone, P. B. Randolph, J. R. Davis, et al., “Search-and-Replace Genome Editing Without Double-Strand Breaks or Donor DNA,” Nature 576, no. 7785 (2019): 149–157.

[42] C. Lu, J. Kuang, T. Shao, et al., “Prime Editing: An All-Rounder for Genome Editing,” International Journal of Molecular Sciences 23, no. 17 (2022): 9862.

[43] K. Omachi and J. H. Miner, “Comparative Analysis of dCas9-VP64 Variants and Multiplexed Guide RNAs Mediating CRISPR Activation,” PLoS One 17, no. 6 (2022): e0270008.

[44] N. Javaid, T. L. H. Pham, and S. Choi, “Functional Comparison Between VP64-dCas9-VP64 and dCas9-VP192 CRISPR Activators in Human Embryonic Kidney Cells,” International Journal of Molecular Sciences 22, no. 1 (2021): 397.

[45] L. A. Syding, P. Nickl, P. Kasparek, and R. Sedlacek, “CRISPR/Cas9 Epigenome Editing Potential for Rare Imprinting Diseases: A Review,” Cells 9, no. 4 (2020): 993.

[46] I. Ansari, A. Chaturvedi, D. Chitkara, and S. Singh, “CRISPR/Cas Mediated Epigenome Editing for Cancer Therapy,” Seminars in Cancer Biology 83 (2022): 570–583.

[47] F. Alkan, A. Wenzel, C. Anthon, et al., “CRISPR-Cas9 Off-Targeting Assessment With Nucleic Acid Duplex Energy Parameters,” Genome Biology 19, no. 1 (2018): 1–13.

[48] Y. Hao, “CRISPR-Cas System: Off-Target Effects and Its Possible Solutions,” (2024), Third International Conference on Biological Engineering and Medical Science (ICBioMed2023), SPIE.

[49] Y. Cai, L. Chen, S. Sun, et al., “CRISPR/Cas9-Mediated Deletion of Large Genomic Fragments in Soybean,” International Journal of Molecular Sciences 19, no. 12 (2018): 3835.

[50] J. P. Guilinger, V. Pattanayak, D. Reyon, et al., “Broad Specificity Profiling of TALENs Results in Engineered Nucleases With Improved DNA-Cleavage Specificity,” Nature Methods 11, no. 4 (2014): 429–435.

[51] H. Manghwar, B. Li, X. Ding, et al., “CRISPR/Cas Systems in Genome Editing: Methodologies and Tools for sgRNA Design, Off-Target Evaluation, and Strategies to Mitigate Off-Target Effects,” Advanced Science 7, no. 6 (2020): 1902312.

[52] M. Naeem, S. Majeed, M. Z. Hoque, and I. Ahmad, “Latest Developed Strategies to Minimize the Off-Target Effects in CRISPR-Cas-Mediated Genome Editing,” Cells 9, no. 7 (2020): 1608.

[53] A. Atkins, C. H. Chung, A. G. Allen, et al., “Off-Target Analysis in Gene Editing and Applications for Clinical Translation of CRISPR/Cas9 in HIV-1 Therapy,” Frontiers in Genome Editing 3 (2021): 673022.

[54] Z. Lei, H. Meng, Y. Zhuang, Q. Zhu, and C. Yi, “Chemical and Biological Approaches to Interrogate Off-Target Effects of Genome Editing Tools,” ACS Chemical Biology 18, no. 2 (2023): 205–217.

[55] C. A. Lino, J. C. Harper, J. P. Carney, and J. A. Timlin, “Delivering CRISPR: A Review of the Challenges and Approaches,” Drug Delivery 25, no. 1 (2018): 1234–1257.

[56] B. H. Yip, “Recent Advances in CRISPR/Cas9 Delivery Strategies,” Biomolecules 10, no. 6 (2020): 839.

[57] W. J. Dai, L. Y. Zhu, Z. Y. Yan, Y. Xu, Q. L. Wang, and X. J. Lu, “CRISPR-Cas9 for In Vivo Gene Therapy: Promise and Hurdles,” Molecular Therapy - Nucleic Acids 5, no. 8 (2016): e349.

[58] Y. Xu and Z. Li, “CRISPR-Cas Systems: Overview, Innovations and Applications in Human Disease Research and Gene Therapy,” Computational and Structural Biotechnology Journal 18 (2020): 2401–2415.

[59] Y. Li, Z. Glass, M. Huang, Z. Y. Chen, and Q. Xu, “Ex Vivo Cell-Based CRISPR/Cas9 Genome Editing for Therapeutic Applications,” Biomaterials 234 (2020): 119711.

[60] F. J. T. Staal, A. Aiuti, and M. Cavazzana, “Autologous Stem-Cell-Based Gene Therapy for Inherited Disorders: State of the Art and Perspectives,” Frontiers in Pediatrics 7 (2019): 443.

[61] F. Davodabadi, B. Farasati Far, S. Sargazi, et al., “Nanomaterials-Based Targeting of Long Non-Coding RNAs in Cancer: A Cutting-Edge Review of Current Trends,” ChemMedChem 19, no. 8 (2024): e202300528.

[62] X. Ou, Q. Ma, W. Yin, X. Ma, and Z. He, “CRISPR/Cas9 Gene-Editing in Cancer Immunotherapy: Promoting the Present Revolution in Cancer Therapy and Exploring More,” Frontiers in Cell and Development Biology 9 (2021): 674467.

[63] Z. Liu, M. Shi, Y. Ren, et al., “Recent Advances and Applications of CRISPR-Cas9 in Cancer Immunotherapy,” Molecular Cancer 22, no. 1 (2023): 35.

[64] A. C. Dong and S. Rivella, “Gene Addition Strategies for Beta-Thalassemia and Sickle Cell Anemia,” Advances in Experimental Medicine and Biology 1013 (2017): 155–176.

[65] C. L. Harteveld, A. Achour, S. J. G. Arkesteijn, et al., “The Hemoglobinopathies, Molecular Disease Mechanisms and Diagnostics,” International Journal of Laboratory Hematology 44, no. 1 (2022): 28–36.

[66] M. Otroj, S. Taymouri, J. Varshosaz, and M. Mirian, “Preparation and Characterization of Dry Powder Containing Sunitinib Loaded PHBV Nanoparticles for Enhanced Pulmonary Delivery,” Journal of Drug Delivery Science and Technology 56 (2020): 101570.

[67] H. Lin, G. Li, X. Peng, et al., “The Use of CRISPR/Cas9 as a Tool to Study Human Infectious Viruses,” Frontiers in Cellular and Infection Microbiology 11 (2021): 590989.

[68] H. J. E. Baddeley and M. Isalan, “The Application of CRISPR/Cas Systems for Antiviral Therapy,” Frontiers in Genome Editing 3 (2021): 745559.

[69] O. W. Kotagama, C. D. Jayasinghe, and T. Abeysinghe, “Era of Genomic Medicine: A Narrative Review on CRISPR Technology as a Potential Therapeutic Tool for Human Diseases,” BioMed Research International 2019 (2019): 1369682.

[70] C. De Masi, P. Spitalieri, M. Murdocca, et al., “Application of CRISPR/Cas9 to Human-Induced Pluripotent Stem Cells: From Gene Editing to Drug Discovery,” Human Genomics 14, no. 1 (2020): 25.

[71] B. C. Geng, K. H. Choi, S. Z. Wang, et al., “A Simple, Quick, and Efficient CRISPR/Cas9 Genome Editing Method for Human Induced Pluripotent Stem Cells,” Acta Pharmacologica Sinica 41, no. 11 (2020): 1427–1432.

[72] A. G. McCloskey, M. G. Miskelly, C. B. T. Moore, et al., “CRISPR/Cas9 Gene Editing Demonstrates Metabolic Importance of GPR55 in the Modulation of GIP Release and Pancreatic Beta Cell Function,” Peptides 125 (2020): 170251.

[73] E. R. Burnight, M. Gupta, L. A. Wiley, et al., “Using CRISPR-Cas9 to Generate Gene-Corrected Autologous iPSCs for the Treatment of Inherited Retinal Degeneration,” Molecular Therapy 25, no. 9 (2017): 1999–2013.

[74] A. A. Dominguez, W. A. Lim, and L. S. Qi, “Beyond Editing: Repurposing CRISPR–Cas9 for Precision Genome Regulation and Interrogation,” Nature Reviews Molecular Cell Biology 17, no. 1 (2016): 5–15.

[75] X. Xu, A. Chemparathy, L. Zeng, et al., “Engineered Miniature CRISPR-Cas System for Mammalian Genome Regulation and Editing,” Molecular Cell 81, no. 20 (2021): 4333–4345.

[76] P. Song, Q. Zhang, Z. Xu, Y. Shi, R. Jing, and D. Luo, “CRISPR/Cas-Based CAR-T Cells: Production and Application,” Biomarker Research 12, no. 1 (2024): 54.

[77] W. Wei, Z.-N. Chen, and K. Wang, “CRISPR/Cas9: A Powerful Strategy to Improve CAR-T Cell Persistence,” International Journal of Molecular Sciences 24, no. 15 (2023): 12317.

[78] T. Lei, Y. Wang, Y. Zhang, et al., “Leveraging CRISPR Gene Editing Technology to Optimize the Efficacy, Safety and Accessibility of CAR T-Cell Therapy,” Leukemia 38 (2024): 1–27.

[79] B. Zhang, “CRISPR/Cas Gene Therapy,” Journal of Cellular Physiology 236, no. 4 (2021): 2459–2481.

[80] I. B. Rogozin, Y. I. Pavlov, A. Goncearenco, et al., “Mutational Signatures and Mutable Motifs in Cancer Genomes,” Briefings in Bioinformatics 19, no. 6 (2018): 1085–1101.

[81] S. Kiri and T. Ryba, “Cancer, Metastasis, and the Epigenome,” Molecular Cancer 23, no. 1 (2024): 154.

[82] P.-K. Raj-Kumar, X. Lin, T. Liu, et al., “Proteogenomic Characterization of Difficult-To-Treat Breast Cancer With Tumor Cells Enriched Through Laser Microdissection,” Breast Cancer Research 26, no. 1 (2024): 76.

[83] Y. Yin, J. Sapida, D. Sukovich, D. Patterson, and A. Tentori, “Unraveling Spatial Complexity of the Tumor Microenvironment: A Whole Transcriptomic Perspective With Visium HD,” Cancer Research 84, no. 6_Supplement (2024): 3645.

[84] A. Goenka, F. Khan, B. Verma, et al., “Tumor Microenvironment Signaling and Therapeutics in Cancer Progression,” Cancer Communications 43, no. 5 (2023): 525–561.

[85] D. Rosenblum, A. Gutkin, R. Kedmi, et al., “CRISPR-Cas9 Genome Editing Using Targeted Lipid Nanoparticles for Cancer Therapy,” Science Advances 6 (2020): eabc9450.

[86] Z. Chen, F. Liu, Y. Chen, et al., “Targeted Delivery of CRISPR/Cas9-Mediated Cancer Gene Therapy via Liposome-Templated Hydrogel Nanoparticles,” Advanced Functional Materials 27 (2017): 1703036.

[87] L. Zhang, D. Kim, and Y. K. Oh, “Lipid Nanoparticle-Mediated Efficient Delivery of CRISPR/Cas9 for Tumor Therapy,” NPG Asia Materials 17, no. 5 (2017): 641–652.

[88] F. M. Behan, F. Iorio, E. Gonçalves, et al., “Prioritisation of Oncology Therapeutic Targets Using CRISPR-Cas9 Screening,” bioRxiv, 2018, 502005.

[89] O. Meca-Cortés, M. Guerra-Rebollo, C. Garrido, S. Borrós, N. Rubio, and J. Blanco, “CRISPR/Cas9-Mediated Knockin Application in Cell Therapy: A Non-Viral Procedure for Bystander Treatment of Glioma in Mice,” Molecular Therapy—Nucleic Acids 8 (2017): 395–403.

[90] C. Liang, F. Li, L. Wang, et al., “Tumor Cell-Targeted Delivery of CRISPR/Cas9 by Aptamer-Functionalized Lipopolymer for Therapeutic Genome Editing of VEGFA in Osteosarcoma,” Biomaterials 147 (2017): 68–85.

[91] G. Wang, R. D. Chow, Z. Bai, et al., “Multiplexed Activation of Endogenous Genes by CRISPRa Elicits Potent Anti-Tumor Immunity,” Nature Immunology 20 (2019): 1494–1505.

[92] H. Tang and J. B. Shrager, “CRISPR/Cas-Mediated Genome Editing to Treat EGFR-Mutant Lung Cancer: A Personalized Molecular Surgical Therapy,” EMBO Molecular Medicine 8 (2016): 83–85.

[93] B. Zhang, P.-Y. Wu, J.-J. Zou, et al., “Efficient CRISPR/Cas9 Gene-Chemo Synergistic Cancer Therapy via a Stimuli-Responsive Chitosan-Based Nanocomplex Elicits Anti-Tumorigenic Pathway Effect,” Chemical Engineering Journal 393 (2020): 124688.

[94] L. Zhang, Y. Li, Q. Chen, Y. Xia, W. Zheng, and X. Jiang, “The Construction of Drug-Resistant Cancer Cell Lines by CRISPR/Cas9 System for Drug Screening,” Science Bulletin 63, no. 21 (2018): 1411–1419.

[95] E. Rayner, M. A. Durin, R. Thomas, et al., “CRISPR-Cas9 Causes Chromosomal Instability and Rearrangements in Cancer Cell Lines, Detectable by Cytogenetic Methods,” CRISPR Journal 2 (2019): 406–416.

[96] E. Kouranova, K. Forbes, G. Zhao, et al., “vCRISPRs for Optimal Targeting: Delivery of CRISPR Components as DNA, RNA, and Protein Into Cultured Cells and Single-Cell Embryos,” Human Gene Therapy 27 (2016): 464–475.

[97] H. Deng, S. Tan, X. Gao, et al., “Cdk5 Knocking out Mediated by CRISPR-Cas9 Genome Editing for PD-L1 Attenuation and Enhanced Antitumor Immunity,” Acta Pharmaceutica Sinica B 10 (2019): 358–373.

[98] K. Szlachta, C. Kuscu, T. Tufan, et al., “CRISPR Knockout Screening Identifies Combinatorial Drug Targets in Pancreatic Cancer and Models Cellular Drug Response,” Nature Communications 9 (2018): 4275.

[99] S. Lin, C. Larrue, N. K. Scheidegger, et al., “An In Vivo CRISPR Screening Platform for Prioritizing Therapeutic Targets in AML,” Cancer Discovery 12 (2020): 432–449.

[100] Y. Liu, G. Zhao, C. F. Xu, Y. L. Luo, Z. D. Lu, and J. Wang, “Systemic Delivery of CRISPR/Cas9 With PEG-PLGA Nanoparticles for Chronic Myeloid Leukemia Targeted Therapy,” Biomaterials Science 6, no. 6 (2018): 1592–1603.

[101] A. H.-K. Cheung, C. Chow, J. Zhang, et al., “Specific Targeting of Point Mutations in EGFR L858R-Positive Lung Cancer by CRISPR/Cas9,” Laboratory Investigation 98 (2018): 968–976.

[102] H. Wang and W. Sun, “CRISPR-Mediated Targeting of HER2 Inhibits Cell Proliferation Through a Dominant Negative Mutation,” Cancer Letters 385 (2017): 137–143.

[103] A. U. Ibrahim, “Genome Engineering Using the CRISPR Cas9 System,” 2019.

[104] P. J. Cook and A. Ventura, “Cancer Diagnosis and Immunotherapy in the Age of CRISPR,” Genes 58 (2019): 233–243.

[105] S. He, “Development of Novel Inducible CRISPR Tools and the Application to Study DNA Damage Responses,” 2023 Johns Hopkins University.

[106] X. Wang, “Gene Mutation-Based and Specific Therapies in Precision Medicine,” Journal of Cellular and Molecular Medicine 20 (2016): 577–580.

[107] A. Noor, A. Bilal, and U. Ali, “Towards Personalized Cancer Care: A Report of CRISPR-Cas9 Applications in Targeted Therapies and Precision Medicine,” Journal of Health and Rehabilitation Research 4, no. 2 (2024): 1375–1380.

[108] A. K. Sharma and A. K. Giri, “Engineering CRISPR/Cas9 Therapeutics for Cancer Precision Medicine,” Frontiers in Genetics 15 (2024): 1309175.

[109] I. Lara-Sáez, Á. Mencía, E. Recuero, et al., “Nonviral CRISPR/Cas9 Mutagenesis for Streamlined Generation of Mouse Lung Cancer Models,” Proceedings of the National Academy of Sciences 121, no. 28 (2024): e2322917121.

[110] T. Park, S. Ye, S. K. Shin, K. Kim, J. K. Hur, and J. W. Hur, “CRISPR-Cas9-Generated Mouse Model of Neurofibromatosis Type 1,” Molecular & Cellular Toxicology 19, no. 2 (2023): 277–282.

[111] H. Park, Y. K. Kang, and G. Shim, “CRISPR/Cas9-Mediated Customizing Strategies for Adoptive T-Cell Therapy,” Pharmaceutics 16, no. 3 (2024): 346.

[112] X. Chen, S. Zhong, Y. Zhan, and X. Zhang, “CRISPR-Cas9 Applications in T Cells and Adoptive T Cell Therapies,” Cellular & Molecular Biology Letters 29, no. 1 (2024): 52.

[113] D. Stefanoudakis, N. Kathuria-Prakash, A. W. Sun, et al., “The Potential Revolution of Cancer Treatment With CRISPR Technology,” Cancers 15, no. 6 (2023): 1813.

[114] S. Dey, M. Devender, S. Rani, and R. K. Pandey, “Recent Advances in CAR T-Cell Engineering Using Synthetic Biology: Paving the Way for Next-Generation Cancer Treatment,” Advances in Protein Chemistry and Structural Biology 140 (2024): 91–156.

[115] A. C. Uscanga-Palomeque, A. K. Chávez-Escamilla, C. A. Alvizo-Báez, et al., “CAR-T Cell Therapy: From the Shop to Cancer Therapy,” International Journal of Molecular Sciences 24, no. 21 (2023): 15688.

[116] S. Depil, P. Duchateau, S. A. Grupp, G. Mufti, and L. Poirot, “'Off-The-Shelf' Allogeneic CAR T Cells: Development and Challenges,” Nature Reviews. Drug Discovery 19, no. 3 (2020): 185–199.

[117] R. Mohty and A. Lazaryan, “‘off-The-Shelf’ Allogeneic Chimeric Antigen Receptor T-Cell Therapy for B-Cell Malignancies: Current Clinical Evidence and Challenges,” Frontiers in Oncology 14 (2024): 1433432.

[118] A. Dimitri, F. Herbst, and J. A. Fraietta, “Engineering the Next-Generation of CAR T-Cells With CRISPR-Cas9 Gene Editing,” Molecular Cancer 21, no. 1 (2022): 78.

[119] J. Ren, X. Zhang, X. Liu, et al., “A Versatile System for Rapid Multiplex Genome-Edited CAR T Cell Generation,” Oncotarget 8, no. 10 (2017): 17002–17011.

[120] A. Al Abbar, S. C. Ngai, N. Nograles, et al., “Induced Pluripotent Stem Cells: Reprogramming Platforms and Applications in Cell Replacement Therapy,” Bioresearch Open Access 9, no. 1 (2020): 121–136.

[121] L. O. Afolabi, A. O. Adeshakin, M. M. Sani, J. Bi, and X. Wan, “Genetic Reprogramming for NK Cell Cancer Immunotherapy With CRISPR/Cas9,” Immunology 158, no. 2 (2019): 63–69.

[122] K. Sekiba, M. Yamagami, M. Otsuka, et al., “Transcriptional Activation of the MICA Gene With an Engineered CRISPR-Cas9 System,” Biochemical and Biophysical Research Communications 486, no. 2 (2017): 521–525.

[123] W. Hu, Z. Zi, Y. Jin, et al., “CRISPR/Cas9-Mediated PD-1 Disruption Enhances Human Mesothelin-Targeted CAR T Cell Effector Functions,” Cancer Immunology, Immunotherapy 68, no. 3 (2019): 365–377.

[124] X. Guo, H. Jiang, B. Shi, et al., “Disruption of PD-1 Enhanced the Anti-Tumor Activity of Chimeric Antigen Receptor T Cells Against Hepatocellular Carcinoma,” Frontiers in Pharmacology 9 (2018): 1118.

[125] M. J. Landrum, J. M. Lee, M. Benson, et al., “ClinVar: Public Archive of Interpretations of Clinically Relevant Variants,” Nucleic Acids Research 44, no. D1 (2016): D862–D868.

[126] W. Hu, G. Wang, D. Huang, et al., “Cancer Immunotherapy Based on Natural Killer Cells: Current Progress and New Opportunities,” Frontiers in Immunology 10 (2019): 1205.

[127] Y. Li, D. L. Hermanson, B. S. Moriarity, and D. S. Kaufman, “Human iPSC-Derived Natural Killer Cells Engineered With Chimeric Antigen Receptors Enhance Anti-Tumor Activity,” Cell Stem Cell 23, no. 2 (2018): 181–192.

[128] “Fate Therapeutics Announces First Patient Treated With IPSC-Derived NK Cell Cancer Immunotherapy FT500 Successfully Completes Initial Safety Assessment,” (2019), https://pipelinereview.com/fate-therapeutics-announces-first-patient-treated-with-ipsc-derived-nk-cell-cancer-immunotherapy-ft500-successfully-completes-initial-safety-assessment/.

[129] X. Lin, Y. Sun, X. Dong, Z. Liu, R. Sugimura, and G. Xie, “IPSC-Derived CAR-NK Cells for Cancer Immunotherapy,” Biomedicine & Pharmacotherapy 165 (2023): 115123.

[130] C. Yang, C. Sun, B. Tan, et al., “Allogeneic Anti-CD19 CAR-T Cells Induce Remission in Refractory Systemic Lupus Erythematosus,” Cell Research 35 (2025): 1–3, https://doi.org/10.1038/s41422-025-01128-1.

[131] D. Mougiakakos, G. Krönke, S. Völkl, et al., “CD19-Targeted CAR T Cells in Refractory Systemic Lupus Erythematosus,” New England Journal of Medicine 385, no. 6 (2021): 567–569.

[132] J. Liu, Y. Zhao, and H. Zhao, “Chimeric Antigen Receptor T-Cell Therapy in Autoimmune Diseases,” Frontiers in Immunology 15 (2024): 1492552.

[133] C. T. Berry, C. S. Frazee, P. J. Herman, et al., “Current Advancements in Cellular Immunotherapy for Autoimmune Disease,” Seminars in Immunopathology 47, no. 1 (2025): 7.

[134] Y. Zhang, J. Wei, J. Cao, et al., “Requirements for Human-Induced Pluripotent Stem Cells,” Cell Proliferation 55, no. 4 (2022): e13182.

[135] J. Hao, A. Ma, L. Wang, et al., “General Requirements for Stem Cells,” Cell Proliferation 53, no. 12 (2020): e12926.

[136] H. Frangoul, D. Altshuler, M. D. Cappellini, et al., “CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia,” New England Journal of Medicine 384, no. 3 (2021): 252–260.

[137] X. Huang, Y. Wang, W. Yan, et al., “Production of Gene-Corrected Adult Beta Globin Protein in Human Erythrocytes Differentiated From Patient iPSCs After Genome Editing of the Sickle Point Mutation,” Stem Cells 33, no. 5 (2015): 1470–1479.

[138] C. Smith, L. Abalde-Atristain, C. He, et al., “Efficient and Allele-Specific Genome Editing of Disease Loci in Human iPSCs,” Molecular Therapy 23, no. 3 (2015): 570–577.

[139] F. Xie, L. Ye, J. C. Chang, et al., “Seamless Gene Correction of β-Thalassemia Mutations in Patient-Specific iPSCs Using CRISPR/Cas9 and piggyBac,” Genome Research 24, no. 9 (2014): 1526–1533.

[140] Y. Wu, D. Liang, Y. Wang, et al., “Correction of a Genetic Disease in Mouse via Use of CRISPR-Cas9,” Cell Stem Cell 13, no. 6 (2013): 659–662.

[141] M. J. Osborn, R. Gabriel, B. R. Webber, et al., “Fanconi Anemia Gene Editing by the CRISPR/Cas9 System,” Human Gene Therapy 26, no. 2 (2015): 114–126.

[142] Y. Pan, N. Shen, S. Jung-Klawitter, et al., “CRISPR RNA-Guided FokI Nucleases Repair a PAH Variant in a Phenylketonuria Model,” Scientific Reports 6 (2016): 35794.

[143] A. L. Firth, T. Menon, G. S. Parker, et al., “Functional Gene Correction for Cystic Fibrosis in Lung Epithelial Cells Generated From Patient iPSCs,” Cell Reports 12, no. 9 (2015): 1385–1390.

[144] Y. Yang, L. Wang, P. Bell, et al., “A Dual AAV System Enables the Cas9-Mediated Correction of a Metabolic Liver Disease in Newborn Mice,” Nature Biotechnology 34, no. 3 (2016): 334–338.

[145] Y. Kang, B. Zheng, B. Shen, et al., “CRISPR/Cas9-Mediated Dax1 Knockout in the Monkey Recapitulates Human AHC-HH,” Human Molecular Genetics 24, no. 25 (2015): 7255–7264.

[146] H. Yin, W. Xue, S. Chen, et al., “Genome Editing With Cas9 in Adult Mice Corrects a Disease Mutation and Phenotype,” Nature Biotechnology 32, no. 6 (2014): 551–553.

[147] Y. Feng, S. Sassi, J. K. Shen, et al., “Targeting CDK11 in Osteosarcoma Cells Using the CRISPR-Cas9 System,” Journal of Orthopaedic Research 33, no. 2 (2015): 199–207.

[148] M. Matano, S. Date, M. Shimokawa, et al., “Modeling Colorectal Cancer Using CRISPR-Cas9-Mediated Engineering of Human Intestinal Organoids,” Nature Medicine 21, no. 3 (2015): 256–262.

[149] R. J. Platt, S. Chen, Y. Zhou, et al., “CRISPR-Cas9 Knockin Mice for Genome Editing and Cancer Modeling,” Cell 159, no. 2 (2014): 440–455.

[150] Q. Ding, A. Strong, K. M. Patel, et al., “Permanent Alteration of PCSK9 With In Vivo CRISPR-Cas9 Genome Editing,” Circulation Research 115, no. 5 (2014): 488–492.

[151] L. Yang, D. Grishin, G. Wang, et al., “Targeted and Genome-Wide Sequencing Reveal Single Nucleotide Variations Impacting Specificity of Cas9 in Human Stem Cells,” Nature Communications 5 (2014): 5507.

[152] L. E. Dow, J. Fisher, K. P. O'Rourke, et al., “Inducible In Vivo Genome Editing With CRISPR-Cas9,” Nature Biotechnology 33, no. 4 (2015): 390–394.

[153] K. J. Carroll, C. A. Makarewich, J. McAnally, et al., “A Mouse Model for Adult Cardiac-Specific Gene Deletion With CRISPR/Cas9,” Proceedings of the National Academy of Sciences of the United States of America 113, no. 2 (2016): 338–343.

[154] K. M. Bloh, P. A. Bialk, A. Gopalakrishnapillai, E. A. Kolb, and E. B. Kmiec, “CRISPR/Cas9-Directed Reassignment of the GATA1 Initiation Codon in K562 Cells to Recapitulate AML in Down Syndrome,” Molecular Therapy–Nucleic Acids 7 (2017): 288–298.

[155] A. G. Bassuk, A. Zheng, Y. Li, S. H. Tsang, and V. B. Mahajan, “Precision Medicine: Genetic Repair of Retinitis Pigmentosa in Patient-Derived Stem Cells,” Scientific Reports 6 (2016): 19969.

[156] L. Swiech, M. Heidenreich, A. Banerjee, et al., “In Vivo Interrogation of Gene Function in the Mammalian Brain Using CRISPR-Cas9,” Nature Biotechnology 33, no. 1 (2015): 102–106.

[157] C. Long, J. R. McAnally, J. M. Shelton, A. A. Mireault, R. Bassel-Duby, and E. N. Olson, “Prevention of Muscular Dystrophy in Mice by CRISPR/Cas9-Mediated Editing of Germline DNA,” Science 345, no. 6201 (2014): 1184–1188.

[158] L. Xu, K. H. Park, L. Zhao, et al., “CRISPR-Mediated Genome Editing Restores Dystrophin Expression and Function in Mdx Mice,” Molecular Therapy 24, no. 3 (2016): 564–569.

[159] M. El Refaey, L. Xu, Y. Gao, et al., “In Vivo Genome Editing Restores Dystrophin Expression and Cardiac Function in Dystrophic Mice,” Circulation Research 121, no. 8 (2017): 923–929.

[160] M. V. Petkova, A. Stantzou, A. Morin, et al., “Live-Imaging of Revertant and Therapeutically Restored Dystrophin in the Dmd(EGFP-Mdx) Mouse Model for Duchenne Muscular Dystrophy,” Neuropathology and Applied Neurobiology 46, no. 6 (2020): 602–614.

[161] K. Lee, M. Conboy, H. M. Park, et al., “Nanoparticle Delivery of Cas9 Ribonucleoprotein and Donor DNA In Vivo Induces Homology-Directed DNA Repair,” Nature Biomedical Engineering 1 (2017): 889–901.

[162] D. G. Ousterout, A. M. Kabadi, P. I. Thakore, W. H. Majoros, T. E. Reddy, and C. A. Gersbach, “Multiplex CRISPR/Cas9-Based Genome Editing for Correction of Dystrophin Mutations That Cause Duchenne Muscular Dystrophy,” Nature Communications 6 (2015): 6244.

[163] L. Wang, F. Yi, L. Fu, et al., “CRISPR/Cas9-Mediated Targeted Gene Correction in Amyotrophic Lateral Sclerosis Patient iPSCs,” Protein & Cell 8, no. 5 (2017): 365–378.

[164] H. Wang, W. Guo, J. Mitra, et al., “Mutant FUS Causes DNA Ligation Defects to Inhibit Oxidative Damage Repair in Amyotrophic Lateral Sclerosis,” Nature Communications 9, no. 1 (2018): 3683.

[165] Y. Zhang, B. Schmid, N. K. Nikolaisen, et al., “Patient iPSC-Derived Neurons for Disease Modeling of Frontotemporal Dementia With Mutation in CHMP2B,” Stem Cell Reports 8, no. 3 (2017): 648–658.

[166] R. Lopez-Gonzalez, D. Yang, M. Pribadi, et al., “Partial Inhibition of the Overactivated Ku80-Dependent DNA Repair Pathway Rescues Neurodegeneration in C9ORF72-ALS/FTD,” Proceedings of the National Academy of Sciences of the United States of America 116, no. 19 (2019): 9628–9633.

[167] G. Krishnan, Y. Zhang, Y. Gu, M. W. Kankel, F. B. Gao, and S. Almeida, “CRISPR Deletion of the C9ORF72 Promoter in ALS/FTD Patient Motor Neurons Abolishes Production of Dipeptide Repeat Proteins and Rescues Neurodegeneration,” Acta Neuropathologica 140, no. 1 (2020): 81–84.

[168] N. A. Ababneh, J. Scaber, R. Flynn, et al., “Correction of Amyotrophic Lateral Sclerosis Related Phenotypes in Induced Pluripotent Stem Cell-Derived Motor Neurons Carrying a Hexanucleotide Expansion Mutation in C9orf72 by CRISPR/Cas9 Genome Editing Using Homology-Directed Repair,” Human Molecular Genetics 29, no. 13 (2020): 2200–2217.

[169] G. Colasante, G. Lignani, S. Brusco, et al., “dCas9-Based Scn1a Gene Activation Restores Inhibitory Interneuron Excitability and Attenuates Seizures in Dravet Syndrome Mice,” Molecular Therapy 28, no. 1 (2020): 235–253.

[170] A. Hendel, R. O. Bak, J. T. Clark, et al., “Chemically Modified Guide RNAs Enhance CRISPR-Cas Genome Editing in Human Primary Cells,” Nature Biotechnology 33, no. 9 (2015): 985–989.

[171] J. Yuan, Y. Ma, T. Huang, et al., “Genetic Modulation of RNA Splicing With a CRISPR-Guided Cytidine Deaminase,” Molecular Cell 72, no. 2 (2018): 380–394.

[172] O. O. Abudayyeh, J. S. Gootenberg, P. Essletzbichler, et al., “RNA Targeting With CRISPR-Cas13,” Nature 550, no. 7675 (2017): 280–284.

[173] B. L. Oakes, C. Fellmann, H. Rishi, et al., “CRISPR-Cas9 Circular Permutants as Programmable Scaffolds for Genome Modification,” Cell 176, no. 1–2 (2019): 254–267.

[174] N. Xie, Y. Zhou, Q. Sun, et al., “Novel Epigenetic Techniques Provided by the CRISPR/Cas9 System,” Stem Cells International 2018 (2018): 7834175.

[175] L. Yang, M. Güell, D. Niu, et al., “Genome-Wide Inactivation of Porcine Endogenous Retroviruses (PERVs),” Science 350, no. 6264 (2015): 1101–1104.

[176] J. S. Chen, E. Ma, L. B. Harrington, et al., “CRISPR-Cas12a Target Binding Unleashes Indiscriminate Single-Stranded DNase Activity,” Science 360, no. 6387 (2018): 436–439.

[177] D. Niu, H. J. Wei, L. Lin, et al., “Inactivation of Porcine Endogenous Retrovirus in Pigs Using CRISPR-Cas9,” Science 357, no. 6357 (2017): 1303–1307.

[178] J. S. Gootenberg, O. O. Abudayyeh, J. W. Lee, et al., “Nucleic Acid Detection With CRISPR-Cas13a/C2c2,” Science 356, no. 6336 (2017): 438–442.

[179] S. Silva, K. Pardee, and L. Pena, “Loop-Mediated Isothermal Amplification (LAMP) for the Diagnosis of Zika Virus: A Review,” Viruses 12, no. 1 (2019): 19.

[180] M. Patchsung, K. Jantarug, A. Pattama, et al., “Clinical Validation of a Cas13-Based Assay for the Detection of SARS-CoV-2 RNA,” Nature Biomedical Engineering 4, no. 12 (2020): 1140–1149.

[181] R. Ding, J. Long, M. Yuan, et al., “CRISPR/Cas System: A Potential Technology for the Prevention and Control of COVID-19 and Emerging Infectious Diseases,” Frontiers in Cellular and Infection Microbiology 11 (2021): 639108.

[182] N. Garg, F. J. Ahmad, and S. Kar, “Recent Advances in Loop-Mediated Isothermal Amplification (LAMP) for Rapid and Efficient Detection of Pathogens,” Current Research in Microbial Sciences 3 (2022): 100120.

[183] H. Lin, G. Li, X. Peng, et al., “The Use of CRISPR/Cas9 as a Tool to Study Human Infectious Viruses. Frontiers in Cellular and Infection,” Microbiology 11 (2021): 11.

[184] L. Etienne, B. H. Hahn, P. M. Sharp, F. A. Matsen, and M. Emerman, “Gene Loss and Adaptation to Hominids Underlie the Ancient Origin of HIV-1,” Cell Host & Microbe 14, no. 1 (2013): 85–92.

[185] L. Etienne, F. Bibollet-Ruche, P. H. Sudmant, L. I. Wu, B. H. Hahn, and M. Emerman, “The Role of the Antiviral APOBEC3 Gene Family in Protecting Chimpanzees Against Lentiviruses From Monkeys,” PLoS Pathogens 11, no. 9 (2015): e1005149.

[186] J.-F. Gélinas, D. R. Gill, and S. C. Hyde, “Multiple Inhibitory Factors Act in the Late Phase of HIV-1 Replication: A Systematic Review of the Literature,” Microbiology and Molecular Biology Reviews 82, no. 1 (2018): e00051-17.

[187] N. K. Duggal and M. Emerman, “Evolutionary Conflicts Between Viruses and Restriction Factors Shape Immunity,” Nature Reviews Immunology 12, no. 10 (2012): 687–695.

[188] J. F. Arias, Y. Iwabu, and K. Tokunaga, “Structural Basis for the Antiviral Activity of BST-2/Tetherin and Its Viral Antagonism,” Frontiers in Microbiology 2 (2011): 250.

[189] S. Konermann, M. D. Brigham, A. E. Trevino, et al., “Genome-Scale Transcriptional Activation by an Engineered CRISPR-Cas9 Complex,” Nature 517, no. 7536 (2015): 583–588.

[190] Y. Zhang, S. Ozono, W. Yao, et al., “CRISPR-Mediated Activation of Endogenous BST-2/Tetherin Expression Inhibits Wild-Type HIV-1 Production,” Scientific Reports 9, no. 1 (2019): 3134.

[191] Z. Noroozi, M. Shamsara, E. Valipour, et al., “Antiproliferative Effects of AAV-Delivered CRISPR/Cas9-Based Degradation of the HPV18-E6 Gene in HeLa Cells,” Scientific Reports 12, no. 1 (2022): 2224.

[192] C. Gao, P. Wu, L. Yu, et al., “The Application of CRISPR/Cas9 System in Cervical Carcinogenesis,” Cancer Gene Therapy 29, no. 5 (2022): 466–474.

[193] M. Teng, Y. Yao, V. Nair, and J. Luo, “Latest Advances of Virology Research Using CRISPR/Cas9-Based Gene-Editing Technology and Its Application to Vaccine Development,” Viruses 13, no. 5 (2021): 779.

[194] B. Shademan, A. Nourazarian, S. Hajazimian, et al., “CRISPR Technology in Gene-Editing-Based Detection and Treatment of SARS-CoV-2,” Frontiers in Molecular Biosciences 8 (2021): 772788.

[195] T. R. Abbott, G. Dhamdhere, Y. Liu, et al., “Development of CRISPR as an Antiviral Strategy to Combat SARS-CoV-2 and Influenza,” Cell 181, no. 4 (2020): 865–876.

[196] L. Ye, J. Wang, A. I. Beyer, et al., “Seamless Modification of Wild-Type Induced Pluripotent Stem Cells to the Natural CCR5Δ32 Mutation Confers Resistance to HIV Infection,” Proceedings of the National Academy of Sciences of the United States of America 111, no. 26 (2014): 9591–9596.

[197] H. Ebina, N. Misawa, Y. Kanemura, and Y. Koyanagi, “Harnessing the CRISPR/Cas9 System to Disrupt Latent HIV-1 Provirus,” Scientific Reports 3 (2013): 2510.

[198] J. Wang and S. R. Quake, “RNA-Guided Endonuclease Provides a Therapeutic Strategy to Cure Latent Herpesviridae Infection,” Proceedings of the National Academy of Sciences of the United States of America 111, no. 36 (2014): 13157–13162.

[199] W. Hu, R. Kaminski, F. Yang, et al., “RNA-Directed Gene Editing Specifically Eradicates Latent and Prevents New HIV-1 Infection,” Proceedings of the National Academy of Sciences of the United States of America 111, no. 31 (2014): 11461–11466.

[200] S. R. Lin, H. C. Yang, Y. T. Kuo, et al., “The CRISPR/Cas9 System Facilitates Clearance of the Intrahepatic HBV Templates In Vivo,” Molecular Therapy - Nucleic Acids 3, no. 8 (2014): e186.

[201] V. Ramanan, A. Shlomai, D. B. T. Cox, et al., “CRISPR/Cas9 Cleavage of Viral DNA Efficiently Suppresses Hepatitis B Virus,” Scientific Reports 5 (2015): 10833.

[202] S. Vinayak, M. C. Pawlowic, A. Sateriale, et al., “Genetic Modification of the Diarrhoeal Pathogen Cryptosporidium parvum,” Nature 523, no. 7561 (2015): 477–480.

[203] F. R. van Diemen, E. M. Kruse, M. J. G. Hooykaas, et al., “CRISPR/Cas9-Mediated Genome Editing of Herpesviruses Limits Productive and Latent Infections,” PLoS Pathogens 12, no. 6 (2016): e1005701.

[204] G. Aimola, D. J. Wight, L. Flamand, and B. B. Kaufer, “Excision of Integrated Human Herpesvirus 6A Genomes Using CRISPR/Cas9 Technology,” Microbiology Spectrum 11, no. 2 (2023): e0076423.

[205] J. Xiao, J. Deng, Q. Zhang, et al., “Targeting Human Cytomegalovirus IE Genes by CRISPR/Cas9 Nuclease Effectively Inhibits Viral Replication and Reactivation,” Archives of Virology 165, no. 8 (2020): 1827–1835.

[206] H. S. Wollebo, A. Bellizzi, R. Kaminski, W. Hu, M. K. White, and K. Khalili, “CRISPR/Cas9 System as an Agent for Eliminating Polyomavirus JC Infection,” PLoS One 10, no. 9 (2015): e0136046.

[207] A. Binnie, E. Fernandes, H. Almeida-Lousada, R. A. de Mello, and P. Castelo-Branco, “CRISPR-Based Strategies in Infectious Disease Diagnosis and Therapy,” Infection 49, no. 3 (2021): 377–385.

[208] E. N. Kirby, B. Shue, P. Q. Thomas, and M. R. Beard, “CRISPR Tackles Emerging Viral Pathogens,” Viruses 13 (2021): 11.

[209] M. Junaid, K. Thirapanmethee, P. Khuntayaporn, and M. T. Chomnawang, “CRISPR-Based Gene Editing in Acinetobacter baumannii to Combat Antimicrobial Resistance,” Pharmaceuticals 16, no. 7 (2023): 920.

[210] D. Lee, P. Muir, S. Lundberg, A. Lundholm, L. Sandegren, and S. Koskiniemi, “A CRISPR-Cas9 System Protecting E. coli Against Acquisition of Antibiotic Resistance Genes,” Scientific Reports 15, no. 1 (2025): 1545.

[211] K. Mikkelsen, J. Z. Bowring, Y. K. NG, et al., “An Endogenous Staphylococcus aureus CRISPR-Cas System Limits Phage Proliferation and Is Efficiently Excised From the Genome as Part of the SCC Mec Cassette,” Microbiology Spectrum 11, no. 4 (2023): e01277–23.

[212] A. V. Ciurea, A. G. Mohan, R. A. Covache-Busuioc, et al., “Unraveling Molecular and Genetic Insights Into Neurodegenerative Diseases: Advances in Understanding Alzheimer's, Parkinson's, and Huntington's Diseases and Amyotrophic Lateral Sclerosis,” International Journal of Molecular Sciences 24, no. 13 (2023): 10809.

[213] K. Kania, W. Ambrosius, W. Kozubski, and A. Kalinowska-Łyszczarz, “The Impact of Disease Modifying Therapies on Cognitive Functions Typically Impaired in Multiple Sclerosis Patients: A Clinician's Review,” Frontiers in Neurology 14 (2023): 1222574.

[214] A. Datta, D. Sarmah, H. Kaur, et al., “Advancement in CRISPR/Cas9 Technology to Better Understand and Treat Neurological Disorders,” Cellular and Molecular Neurobiology 43, no. 3 (2023): 1019–1035.

[215] B. György, C. Lööv, M. P. Zaborowski, et al., “CRISPR/Cas9 Mediated Disruption of the Swedish APP Allele as a Therapeutic Approach for Early-Onset Alzheimer's Disease,” Molecular Therapy - Nucleic Acids 11 (2018): 429–440.

[216] M. Ortiz-Virumbrales, C. L. Moreno, I. Kruglikov, et al., “CRISPR/Cas9-Correctable Mutation-Related Molecular and Physiological Phenotypes in iPSC-Derived Alzheimer's PSEN2 (N141I) Neurons,” Acta Neuropathologica Communications 5, no. 1 (2017): 77.

[217] S. P. Raikwar, R. Thangavel, I. Dubova, et al., “Targeted Gene Editing of Glia Maturation Factor in Microglia: A Novel Alzheimer's Disease Therapeutic Target,” Molecular Neurobiology 56, no. 1 (2019): 378–393.

[218] G. Colasante, Y. Qiu, L. Massimino, et al., “In Vivo CRISPRa Decreases Seizures and Rescues Cognitive Deficits in a Rodent Model of Epilepsy,” Brain 143, no. 3 (2020): 891–905.

[219] J. W. Shin, K. H. Kim, M. J. Chao, et al., “Permanent Inactivation of Huntington's Disease Mutation by Personalized Allele-Specific CRISPR/Cas9,” Human Molecular Genetics 25, no. 20 (2016): 4566–4576.

[220] N. Kolli, M. Lu, P. Maiti, J. Rossignol, and G. Dunbar, “CRISPR-Cas9 Mediated Gene-Silencing of the Mutant Huntingtin Gene in an In Vitro Model of Huntington's Disease,” International Journal of Molecular Sciences 18, no. 4 (2017): 754.

[221] A. M. Monteys, S. A. Ebanks, M. S. Keiser, and B. L. Davidson, “CRISPR/Cas9 Editing of the Mutant Huntingtin Allele In Vitro and In Vivo,” Molecular Therapy 25, no. 1 (2017): 12–23.

[222] S. Yang, R. Chang, H. Yang, et al., “CRISPR/Cas9-Mediated Gene Editing Ameliorates Neurotoxicity in Mouse Model of Huntington's Disease,” Journal of Clinical Investigation 127, no. 7 (2017): 2719–2724.

[223] B. Kantor, L. Tagliafierro, J. Gu, et al., “Downregulation of SNCA Expression by Targeted Editing of DNA Methylation: A Potential Strategy for Precision Therapy in PD,” Molecular Therapy 26, no. 11 (2018): 2638–2649.

[224] Y. Chen, M. Xiong, Y. Dong, et al., “Chemical Control of Grafted Human PSC-Derived Neurons in a Mouse Model of Parkinson's Disease,” Cell Stem Cell 18, no. 6 (2016): 817–826.

[225] J. Lee, D. Bayarsaikhan, R. Arivazhagan, et al., “CRISPR/Cas9 Edited sRAGE-MSCs Protect Neuronal Death in Parkinson's Disease Model,” International Journal of Stem Cells 12, no. 1 (2019): 114–124.

[226] M. Yao, Q. Yang, M. Lian, et al., “Generation of Dip2a Homozygous Knockout Murine ES Cell Line IBMSe001-A-1 via CRISPR/Cas9 Technology,” Stem Cell Research 45 (2020): 101778.

[227] F. A. Saad, J. F. Saad, G. Siciliano, L. Merlini, and C. Angelini, “Duchenne Muscular Dystrophy Gene Therapy,” Current Gene Therapy 24, no. 1 (2024): 17–28.

[228] T. Gruenewald, T. E. Seeman, T. H. Choo, et al., “Cardiovascular Variability, Sociodemographics, and Biomarkers of Disease: The MIDUS Study,” Frontiers in Physiology 14 (2023): 1234427.

[229] J. H. Goell and I. B. Hilton, “CRISPR/Cas-Based Epigenome Editing: Advances, Applications, and Clinical Utility,” Trends in Biotechnology 39, no. 7 (2021): 678–691.

[230] J. Taniguchi, Y. Feng, G. N. Pandian, et al., “Biomimetic Artificial Epigenetic Code for Targeted Acetylation of Histones,” Journal of the American Chemical Society 140, no. 23 (2018): 7108–7115.

[231] M. P. Gemberling, K. Siklenka, E. Rodriguez, et al., “Transgenic Mice for In Vivo Epigenome Editing With CRISPR-Based Systems,” Nature Methods 18, no. 8 (2021): 965–974.

[232] Z. Mészár, É. Kókai, R. Varga, et al., “CRISPR/Cas9-Based Mutagenesis of Histone H3. 1 in Spinal Dynorphinergic Neurons Attenuates Thermal Sensitivity in Mice,” International Journal of Molecular Sciences 23, no. 6 (2022): 3178.

[233] A. Singh, H. Irfan, E. Fatima, Z. Nazir, A. Verma, and A. Akilimali, “Revolutionary Breakthrough: FDA Approves CASGEVY, the First CRISPR/Cas9 Gene Therapy for Sickle Cell Disease,” Annals of Medicine and Surgery 86, no. 8 (2024): 4555–4559.

[234] D. V. Parums, “First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and Transfusion-Dependent β-Thalassemia,” Medical Science Monitor: International Medical Journal of Experimental and Clinical Research 30 (2024): e944204.

[235] S. Kotit, “Lessons From the First-In-Human In Vivo CRISPR/Cas9 Editing of the TTR Gene by NTLA-2001 Trial in Patients With Transthyretin Amyloidosis With Cardiomyopathy,” Global Cardiology Science & Practice 2023, no. 1 (2023): e202304.

[236] H. J. Longhurst, K. Lindsay, R. S. Petersen, et al., “CRISPR-Cas9 In Vivo Gene Editing of KLKB1 for Hereditary Angioedema,” New England Journal of Medicine 390, no. 5 (2024): 432–441.

[237] S. O'Brien, L. J. Nastoupil, J. Essell, et al., “A First-In-Human Phase 1, Multicenter, Open-Label Study of CB-010, a Next-Generation CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy With a PD-1 Knockout, in Patients With Relapsed/Refractory b Cell Non-Hodgkin Lymphoma (ANTLER Study),” Blood 140, no. Supplement 1 (2022): 9457–9458.

[238] S. K. Pal, B. Tran, J. B. A. G. Haanen, et al., “CD70-Targeted Allogeneic CAR T-Cell Therapy for Advanced Clear Cell Renal Cell Carcinoma,” Cancer Discovery 14, no. 7 (2024): 1176–1189.

[239] T. Horie and K. Ono, “VERVE-101: A promising CRISPR-Based Gene Editing Therapy that Reduces LDL-C and PCSK9 Levels in HeFH Patients,” European Heart Journal - Cardiovascular Pharmacotherapy 10, no. 2 (2024): 89–90.

[240] “CRISPR Gene Therapy EBT-101 Does Not Prevent HIV Viral Rebound,” (2024), https://www.aidsmap.com/news/may-2024/crispr-gene-therapy-ebt-101-does-not-prevent-hiv-viral-rebound.

[241] K. Khambhati, G. Bhattacharjee, and V. Singh, “Current Progress in CRISPR-Based Diagnostic Platforms,” Journal of Cellular Biochemistry 120, no. 3 (2019): 2721–2725.

[242] Y. Li, S. Li, J. Wang, and G. Liu, “CRISPR/Cas Systems Towards Next-Generation Biosensing,” Trends in Biotechnology 37, no. 7 (2019): 730–743.

[243] W. Wang, J. Hou, N. Zheng, et al., “Keeping Our Eyes on CRISPR: The ‘Atlas’ of Gene Editing,” Cell Biology and Toxicology 35 (2019): 285–288.

[244] X.-Y. Qiu, L. Y. Zhu, C. S. Zhu, et al., “Highly Effective and Low-Cost microRNA Detection With CRISPR-Cas9,” ACS Synthetic Biology 7, no. 3 (2018): 807–813.

[245] L. Li, G. Shen, M. Wu, J. Jiang, Q. Xia, and P. Lin, “CRISPR-Cas-Mediated Diagnostics,” Trends in Biotechnology 40 (2022): 1326–1345.

[246] B. Durán-Vinet, K. Araya-Castro, J. Calderón, et al., “CRISPR/Cas13-Based Platforms for a Potential Next-Generation Diagnosis of Colorectal Cancer Through Exosomes Micro-RNA Detection: A Review,” Cancers (Basel) 13, no. 18 (2021): 4640.

[247] H. Yang, P. Bailey, and C. Pilarsky, “CRISPR Cas9 in Pancreatic Cancer Research,” Frontiers in Cell and Development Biology 7 (2019): 239.

[248] R. C. Ramaker, A. A. Hardigan, E. R. Gordon, C. A. Wright, R. M. Myers, and S. J. Cooper, “Pooled CRISPR Screening in Pancreatic Cancer Cells Implicates Co-Repressor Complexes as a Cause of Multiple Drug Resistance via Regulation of Epithelial-To-Mesenchymal Transition,” BMC Cancer 21, no. 1 (2021): 632.

[249] X. Wei, J. Yang, S. J. Adair, et al., “Targeted CRISPR Screening Identifies PRMT5 as Synthetic Lethality Combinatorial Target With Gemcitabine in Pancreatic Cancer Cells,” Proceedings of the National Academy of Sciences of the United States of America 117, no. 45 (2020): 28068–28079.

[250] V. Skripova, I. Serebriiskii, R. Kiyamova, and I. Astsaturov, “Application of CRISPR/Cas9 System for Identification of Genes Involved in the Regulation of Pancreatic Cancer Cells Platinum Sensitivity,” Annals of Oncology 29 (2018): viii46–viii47.

[251] V. Skripova, R. Vlasenkova, Y. Zhou, et al., “Identification of New Regulators of Pancreatic Cancer Cell Sensitivity to Oxaliplatin and Cisplatin,” Molecules 27, no. 4 (2022): 1289.

[252] J. Hou, Z. He, T. Liu, et al., “Evolution of Molecular Targeted Cancer Therapy: Mechanisms of Drug Resistance and Novel Opportunities Identified by CRISPR-Cas9 Screening,” Frontiers in Oncology 12 (2022): 755053.

[253] F. Zhang, Q. Fan, K. Ren, A. D. Auerbach, and P. R. Andreassen, “FANCJ/BRIP1 Recruitment and Regulation of FANCD2 in DNA Damage Responses,” Chromosoma 119, no. 6 (2010): 637–649.

[254] W. Kim, S. Lee, H. S. Kim, et al., “Targeting Mutant KRAS With CRISPR-Cas9 Controls Tumor Growth,” Genome Research 28, no. 3 (2018): 374–382.

[255] L. Bai, Y. Pang, T. Wang, et al., “SPEAR: CRISPR-Mediated Ultrasensitive, Specific and Rapid One-Pot Detection Strategy for Cancer-Related SNPs,” Theranostics 15, no. 8 (2025): 3275–3288.

[256] J. H. Lo, L. Hao, M. D. Muzumdar, et al., “iRGD-Guided Tumor-Penetrating Nanocomplexes for Therapeutic siRNA Delivery to Pancreatic Cancer,” Molecular Cancer Therapeutics 17, no. 11 (2018): 2377–2388.

[257] D. Nikitovic, E. Kukovyakina, A. Berdiaki, et al., “Enhancing Tumor Targeted Therapy: The Role of iRGD Peptide in Advanced Drug Delivery Systems,” Cancers (Basel) 16, no. 22 (2024): 3768.

[258] V. Uppada, M. Gokara, and G. K. Rasineni, “Diagnosis and Therapy With CRISPR Advanced CRISPR Based Tools for Point of Care Diagnostics and Early Therapies,” Gene 656 (2018): 22–29.

[259] D. V. Foss, M. L. Hochstrasser, and R. C. Wilson, “Clinical Applications of CRISPR-Based Genome Editing and Diagnostics,” Transfusion 59, no. 4 (2019): 1389–1399.

[260] S. Woloshin, N. Patel, and A. S. Kesselheim, “False Negative Tests for SARS-CoV-2 Infection—Challenges and Implications,” New England Journal of Medicine 383, no. 6 (2020): e38.

[261] F. Palaz, A. K. Kalkan, A. Tozluyurt, and M. Ozsoz, “CRISPR-Based Tools: Alternative Methods for the Diagnosis of COVID-19,” Clinical Biochemistry 89 (2021): 1–13.

[262] A. Eid and M. M. Mahfouz, “Genome Editing: The Road of CRISPR/Cas9 From Bench to Clinic,” Experimental & Molecular Medicine 48, no. 10 (2016): e265.

[263] E. Hanna, C. Rémuzat, P. Auquier, and M. Toumi, “Gene Therapies Development: Slow Progress and Promising Prospect,” Journal of Market Access & Health Policy 5, no. 1 (2017): 1265293.

[264] N. Javaid and S. Choi, “CRISPR/Cas System and Factors Affecting Its Precision and Efficiency,” Frontiers in Cell and Development Biology 9 (2021): 761709.

[265] C. J. Bashor, I. B. Hilton, H. Bandukwala, D. M. Smith, and O. Veiseh, “Engineering the Next Generation of Cell-Based Therapeutics,” Nature Reviews Drug Discovery 21, no. 9 (2022): 655–675.

[266] M. F. Wangler, S. Yamamoto, H. T. Chao, et al., “Model Organisms Facilitate Rare Disease Diagnosis and Therapeutic Research,” Genetics 207, no. 1 (2017): 9–27.

[267] R. Szatanek, M. Baj-Krzyworzeka, J. Zimoch, M. Lekka, M. Siedlar, and J. Baran, “The Methods of Choice for Extracellular Vesicles (EVs) Characterization,” International Journal of Molecular Sciences 18, no. 6 (2017): 1153.

[268] S. El Andaloussi, I. Mäger, X. O. Breakefield, and M. J. A. Wood, “Extracellular Vesicles: Biology and Emerging Therapeutic Opportunities,” Nature Reviews Drug Discovery 12, no. 5 (2013): 347–357.

[269] M. Colombo, G. Raposo, and C. Théry, “Biogenesis, Secretion, and Intercellular Interactions of Exosomes and Other Extracellular Vesicles,” Annual Review of Cell and Developmental Biology 30 (2014): 255–289.

[270] M. J. Haney, N. L. Klyachko, Y. Zhao, et al., “Exosomes as Drug Delivery Vehicles for Parkinson's Disease Therapy,” Journal of Controlled Release 207 (2015): 18–30.

[271] B. Shen, J. Zhang, H. Wu, et al., “Generation of Gene-Modified Mice via Cas9/RNA-Mediated Gene Targeting,” Cell Research 23, no. 5 (2013): 720–723.

RIGHTS & PERMISSIONS

2025 The Author(s). Cell Proliferation published by Beijing Institute for Stem Cell and Regenerative Medicine and John Wiley & Sons Ltd.